
    
The genomic variant c.126_129del p.Phe42LeufsTer19 rs80356821 is located on the HBB gene, which encodes the beta-globin subunit of hemoglobin. Hemoglobin is responsible for oxygen transport in the blood, and alterations in the HBB gene can lead to disorders such as beta-thalassemia and sickle cell disease. The c.126_129del variant results in a frameshift, leading to a premature termination codon at the 19th amino acid downstream from the site of the deletion. This change produces a truncated beta-globin protein, which can affect the normal function of hemoglobin and result in disease.The c.126_129del variant has been reported in multiple studies and is associated with beta-thalassemia, a condition characterized by reduced or absent synthesis of the beta-globin chains of hemoglobin. This variant was found in 5 out of 17 cases in a study population, representing a constituent ratio of 29.41% among beta-thalassemia mutations in that particular cohort [1]. In another study, the c.126_129del variant was reported with a frequency of 9.2% among different HBB gene mutations [2]. Furthermore, the variant was identified in cases of beta-thalassemia in a study that utilized Sanger sequencing of cord blood and non-invasive prenatal testing (NIPT) targeted capture sequencing [3].In a comprehensive study of beta-thalassemia patients, the c.126_129del variant was one of the mutations identified, further confirming its association with the disease [4]. Additionally, a large-scale study in southern Vietnam documented the c.126_129del variant among other mutations in the HBB gene, emphasizing its relevance in the genetic landscape of beta-thalassemia in Asian populations [5].ClinVar has recorded a total of 9 pathogenic submissions for the rs80356821 variant, supporting its clinical significance in relation to beta-thalassemia. The frameshift nature of the variant is consistent with the type of molecular defect that typically leads to the production of an abnormal or non-functional protein, contributing to the pathophysiology of hemoglobinopathies.

ゲノム変異 c.126_129del p.Phe42LeufsTer19 rs80356821 は、ヘモグロビンのβグロビンサブユニットをコードする HBB 遺伝子に位置しています。ヘモグロビンは血液中の酸素輸送を担っており、HBB 遺伝子の変化はβサラセミアや鎌状赤血球症などの疾患を引き起こす可能性があります。c.126_129del 変異はフレームシフトを引き起こし、欠失部位から19番目のアミノ酸で早期終止コドンを生成します。この変化により短縮されたβグロビンタンパク質が生成され、ヘモグロビンの正常な機能に影響を与え、疾患を引き起こす可能性があります。

c.126_129del 変異は複数の研究で報告されており、βサラセミアと関連しています。βサラセミアはヘモグロビンのβグロビン鎖の合成が減少または欠如する状態として特徴付けられます。この変異はある研究集団で17例中5例に見られ、該当コホートにおけるβサラセミア変異の構成比率は29.41%でした [1]。別の研究では、c.126_129del 変異は異なる HBB 遺伝子変異の中で頻度が9.2%と報告されました [2]。さらに、この変異は臍帯血のサンガーシーケンシングおよび非侵襲的出生前検査（NIPT）のターゲットキャプチャーシーケンシングを利用した研究でβサラセミアの症例で確認されました [3]。

βサラセミア患者の包括的な研究では、c.126_129del 変異が疾患との関連をさらに確認する変異の1つとして特定されました [4]。加えて、ベトナム南部での大規模研究では、HBB 遺伝子の他の変異とともに c.126_129del 変異が記録され、アジアの集団におけるβサラセミアの遺伝的背景におけるその重要性が強調されました [5]。

ClinVar では、rs80356821 変異に関して計9件の病原性の提出が記録されており、βサラセミアとの臨床的関連性を支持しています。この変異のフレームシフト性は、通常異常または機能不全のタンパク質を生成し、ヘモグロビン異常症の病態生理に寄与する分子欠陥のタイプと一致しています。
    
## References
- [1] Shao B et al. (2024). "Mutation spectrum of thalassemia among pre-pregnant adults in the Jiangsu Province by capillary electrophoresis-based multiplex PCR assay." Molecular genetics & genomic medicine, 12(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38112059/)
- [2] Lee JS et al. (2021). "Molecular basis and diagnosis of thalassemia." Blood research, 56(S1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/33935034/)
- [3] Luo Y et al. (2019). "Pilot study of a novel multi-functional noninvasive prenatal test on fetus aneuploidy, copy number variation, and single-gene disorder screening." Molecular genetics & genomic medicine, 7(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/30767419/)
- [4] Zulkeflee RH et al. (2023). "Application of Targeted Next-Generation Sequencing for the Investigation of Thalassemia in a Developing Country: A Single Center Experience." Diagnostics (Basel, Switzerland), 13(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/37189480/)
- [5] Xinh PT et al. (2022). "Spectrum of HBB gene mutations among 696 beta-thalassemia patients and carriers in Southern Vietnam." Molecular biology reports, 49(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/35023007/)
- [6] Kumar R et al. (2015). "Profiling beta Thalassemia Mutations in Consanguinity and Nonconsanguinity for Prenatal Screening and Awareness Programme." Advances in hematology, 2015() [PubMed](https://pubmed.ncbi.nlm.nih.gov/26576156/)
- [7] Shah PS et al. (2017). "Mutation analysis of beta-thalassemia in East-Western Indian population: a recent molecular approach." The application of clinical genetics, 10() [PubMed](https://pubmed.ncbi.nlm.nih.gov/28546763/)
- [8] Christopher AF et al. (2013). "Unique pattern of mutations in beta-thalassemia patients in Western Uttar Pradesh." Indian journal of human genetics, 19(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/24019624/)
- [9] Bashyam MD et al. (2004). "Molecular genetic analyses of beta-thalassemia in South India reveals rare mutations in the beta-globin gene." Journal of human genetics, 49(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/15278762/)
- [10] Li SY et al. (2022). "[Hematological Characteristics of Different Genotypes of Thalassemia among Reproductive Population in Chongqing]." Zhongguo shi yan xue ye xue za zhi, 30(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/35123629/)
- [11] Hyun Ji Lee et al. (2018). "Increased Prevalence of Thalassemia in Young People in Korea: Impact of Increasing Immigration" Annals of Laboratory Medicine, 39 [PubMed](https://pubmed.ncbi.nlm.nih.gov/30430775/)
- [12] Y. Wan et al. (2024). "Prediction the Occurrence of Thalassemia With Hematological Phenotype by Diagnosis of Abnormal HbA1c" Journal of Clinical Laboratory Analysis, 38 [PubMed](https://pubmed.ncbi.nlm.nih.gov/39317177/)
- [13] Vihinen M et al. (2021). "Systematics for types and effects of RNA variations." RNA biology, 18(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/32951567/)
- [14] Chetruengchai W et al. (2024). "Carrier frequency estimation of pathogenic variants of autosomal recessive and X-linked recessive mendelian disorders using exome sequencing data in 1,642 Thais." BMC medical genomics, 17(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38167091/)
- [15] Zhou H et al. (2024). "Deferasirox-induced hyperammonemia and Fanconi syndrome: a case report." Frontiers in pediatrics, 12() [PubMed](https://pubmed.ncbi.nlm.nih.gov/39449753/)

    
## ClinVar Submissions
- **[RCV000020328](https://www.ncbi.nlm.nih.gov/clinvar/RCV000020328/)**: beta Thalassemia
- **[RCV000508554](https://www.ncbi.nlm.nih.gov/clinvar/RCV000508554/)**: not provided
- **[RCV002465488](https://www.ncbi.nlm.nih.gov/clinvar/RCV002465488/)**: Beta-thalassemia HBB/LCRB
- **[RCV001004569](https://www.ncbi.nlm.nih.gov/clinvar/RCV001004569/)**: Hb SS disease
- **[RCV001262999](https://www.ncbi.nlm.nih.gov/clinvar/RCV001262999/)**: Fetal hemoglobin quantitative trait locus 1
- **[RCV002426507](https://www.ncbi.nlm.nih.gov/clinvar/RCV002426507/)**: Inborn genetic diseases
- **[RCV002496380](https://www.ncbi.nlm.nih.gov/clinvar/RCV002496380/)**: Dominant beta-thalassemia (and 8 more)
- **[RCV003914848](https://www.ncbi.nlm.nih.gov/clinvar/RCV003914848/)**: HBB-related condition
- **[RCV000016673](https://www.ncbi.nlm.nih.gov/clinvar/RCV000016673/)**: Beta zero thalassemia

    